MEGAPTH Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Teriparatide [r-human parathyroid hormone (1-34)]

Indications/Uses

Postmenopausal women w/ osteoporosis at high risk for fracture. Increase of bone mass in men w/ primary or hypogonadal osteoporosis at high risk for fracture. Osteoporosis associated w/ sustained systemic glucocorticoid therapy at high risk for fracture.

Click to view MEGAPTH detailed prescribing information

Dosage/Direction for Use

SC 20 mcg once daily. Treatment duration: Not >2 yr.

Click to view MEGAPTH detailed prescribing information

Overdosage

View MEGAPTH overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. Preexisting hypercalcaemia; metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism & Paget's disease of bone); unexplained elevations of alkaline phosphatase; prior external beam or implant radiation therapy to the skeleton; patients w/ skeletal malignancies or bone metastases. Severe renal impairment.

Click to view MEGAPTH detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view MEGAPTH detailed prescribing information

Special Precautions

Not to be prescribed for patients at increased baseline risk for osteosarcoma including those w/ Paget's disease of bone or unexplained elevations of alkaline phosphatase, or prior external beam or implant radiation therapy involving the skeleton. Isolated episodes of transient orthostatic hypotension. May increase urinary Ca excretion. Patients w/ active or recent urolithiasis; hepatic, renal & cardiac disease. Concomitant use w/ digitalis. Refrain from driving or the use of machines until symptoms (eg, transient, orthostatic hypotension or dizziness) have subsided. Moderate renal impairment. Not to be used during pregnancy & lactation, in ped patients or young adults w/ open epiphyses.

Click to view MEGAPTH detailed prescribing information

Use In Pregnancy & Lactation

Click to view MEGAPTH detailed prescribing information

Adverse Reactions

Pain in limb. Nausea, dizziness, headache. Anemia; hypercholesterolemia; depression; sciatica; vertigo; palpitation; hypotension; dyspnea; vomiting, hiatus hernia, GERD; increased sweating; muscle cramps; fatigue, chest pain, asthenia.

Drug Interactions

Increased serum Ca in concomitant use w/ digoxin.

Click to view MEGAPTH detailed prescribing information

Storage

View MEGAPTH storage conditions for details to ensure optimal shelf-life.

Description

View MEGAPTH description for details of the chemical structure and excipients (inactive components).

Action

View MEGAPTH mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Agents Affecting Bone Metabolism

ATC Classification

H05AA02 - teriparatide ; Belongs to the class of parathyroid hormones and analogues. Used in the management of calcium homeostasis.

Regulatory Classification

POM

Presentation/Packing

Form

MEGAPTH inj 750 mcg/3 mL

Packing/Price

1's

MEGAPTH

teriparatide

Manufacturer:

Virchow Biotech

Distributor:

Maxxcare

Marketer:

Mega Lifesciences